Polyethylene glycol-conjugated adenosine phosphorylase: Development of alternative enzyme therapy for adenosine deaminase deficiency

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1637, Issue 2, 2003, Pages 171-177

  Brewerton, Lee J ^a   Fung, Ernest ^a   Snyder, Floyd F ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Adenosine phosphorylase; PEG AP; Polyethylene glycol; Purine nucleoside phosphorylase

Indexed keywords

ADENOSINE PHOSPHATE PHOSPHATASE; DEOXYADENOSINE; INOSINE; MACROGOL DERIVATIVE; POLYETHYLENEGLYCOL CONJUGATED ADENOSINE PHOSPHORYLASE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; URIC ACID;

ADENOSINE DEAMINASE DEFICIENCY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CATALYSIS; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TISSUE LEVEL; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME THERAPY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REVIEW; URIC ACID URINE LEVEL;

EID: 0037456687     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4439(03)00016-4     Document Type: Review

References (33)

1. Maynes J.T., Yam W.-S., Jenuth J.P., Yuan R.G., Litster S.A., Phipps B.M., Snyder F.F. Design of an adenosine phosphorylase by active-site modification of murine purine nucleoside phosphorylase. Enzyme kinetics and molecular dynamics simulation of Asn-243 and Lys-244 substitutions of purine nucleoside phosphorylase. Biochem. J. 344:1999;585-592.
2. Hershfield M.S. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin. Immunol. Immunopathol. 76:1995;S228-S232.
3. Hershfield M.S. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. Semin. Hematol. 35:1998;291-298.
4. Chum J.D., Lee N., Kobayashi R.H., Chaffee S., Hershfield M.S., Stiehm E.R. Suppression of an antibody to adenosine-deaminase (ADA) in an ADA-deficient patient receiving polyethylene glycol modified adenosine deaminase. Ann. Allergy. 70:1993;462-466.
5. Marwaha V.R., Italia D.H., Esper F., Hostoffer R.W. Extreme thrombocytosis in response to PEG-ADA: early therapeutic and risk indicator. Clin. Pediatr. 39:2000;183-186.
6. Hughes B.W., King S.A., Allan P.W., Parker W.B., Sorscher E.J. Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase. J. Biol. Chem. 273:1998;2322-2328.
7. Gadi V.K., Alexander S.D., Kudlow J.E., Allan P., Parker W.B., Sorsher E.J. Bystander sensitization by E. coli PNP and 6-methylpurine deoxyriboside. Gene Ther. 20:2000;1738-1743.
8. Mao C., Cook W.J., Zhou M., Koszalka G.W., Krenitsky T.A., Ealick S.E. The crystal structure of Escherichia coli purine nucleoside phosphorylase: a comparison with the human enzyme reveals a conserved topology. Structure. 5:1997;1373-1383.
9. Bzowska A., Kulikowska E., Shugar D. Properties of purine nucleoside phosphorylase (PNP) of mammalian and bacterial origin. Z. Naturforsch., C. 45:1990;59-70.
10. Trembacz H., Jezewska M.M. Specific adenosine phosphorylase from hepatopancreas of gastropod Helix pomatia. Comp. Biochem. Physiol., B. 104:1993;481-487.
11. Munagala N., Wang C.C. PNP from Trichonomas vaginalis is a homologue of the bacterial enzyme. Biochemistry. 41:2002;10382-10389.
12. Kicska G.A., Tyler P.C., Evans G.B., Furneaux R.H., Kim K., Schramm V.L. Transition state analogue inhibitors of purine nucleoside phosphorylase from Plasmodium falciparum. J. Biol. Chem. 277:2002;3219-3225.
13. Snyder F.F., Jenuth J.P., Mably E.R., Mangat R.K. Point mutations at the purine nucleoside phosphorylase locus impair thymocyte differentiation in the mouse. Proc. Natl. Acad. Sci. U. S. A. 94:1997;2522-2527.
14. Tan Y., Sun X., Xu M., An Z., Tan X., Han Q., Miljkovic D.A., Yang M., Hoffman R.M. Polyethylene glycol conjugation of recombinant methioninase for cancer therapy. Protein Expr. Purif. 12:1998;45-52.
15. Watson E., Shah B., DePrince R., Hendren R.W., Nelson R. Matrix-assisted laser desorption mass spectrometric analysis of a pegylated recombinant protein. BioTechniques. 16:1994;278-281.
16. Veronese F.M. PEGylation: a review of problems and solutions. Biomaterials. 22:2001;405-417.
17. Carson D.A., Wasson D.B., Taetle R., Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 62:1983;737-743.
18. Beutler E., Carson D.A. 2-Chlorodeoxyadenosine: hairy cell leukemia takes a surprising turn. Blood Cells. 19:1993;559-568.
19. Le Tissier P.R., Peters J., Skidmore C.J. Development of an assay method for purine catabolic enzymes in the mouse and its adaptation for use on an autoanalyzer. Anal. Biochem. 222:1994;168-175.
20. Micheli V., Rocchigiani M., Pompucci G. An HPLC-linked assay of phosphoribosylpyrophosphate synthetase activity in the erythrocytes of adults and children with neurological disorders. Clin. Chim. Acta. 227:1994;79-86.
21. Mably E.R., Jenuth J.P., Fung E., Snyder F.F. Secondary deficiency of deoxyguanosine kinase associated with purine nucleoside phosphorylase deficiency in the mouse. Biochim. Biophys. Acta. 999:1994;333-444.
22. Snyder F.F., Hershfield M.S., Seegmiller J.E. Cytotoxic and metabolic effects of adenosine and adenine on human lymphoblasts. Cancer Res. 38:1978;2357-2362.
23. Francis G.E., Fisher D., Delgado C., Malik F., Gardiner A., Neale D. PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques. Int. J. Hematol. 68:1998;1-18.
24. Roberts M.J., Harris J.M. Attachment of degradable poly(ethylene glycol) to proteins has the potential to increase therapeutic efficacy. J. Pharm. Sci. 87:1998;1440-1445.
25. Delgado C., Francis G.E., Fisher D. The uses and properties of PEG-linked proteins. Crit Rev. Ther. Drug Carr. Syst. 9:1992;249-304.
26. Hershfield M.S., Chaffee S., Koro-Johnson L., Mary A., Smith A.A., Short S.A. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proc. Natl. Acad. Sci. U. S. A. 88:1991;7185-7189.
27. Monfardini C., Schiavon O., Caliceti P., Morpurgo M., Harris J.M., Veronese F.M. A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug. Chem. 6:1995;62-69.
28. Motzer R.J., Rakhit A., Ginsberg M., Rittweger K., Vuky J., Yu R., Fettner S., Hooftman L. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J. Clin. Oncol. 19:2001;1312-1319.
29. Barnard D.L. Pegasys (Hoffmann-La Roche). Curr. Opin. Investig. Drugs. 2:2001;1530-1538.
30. Rajender R.K., Modi M.W., Pedder S. Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. Adv. Drug Deliv. Rev. 54:2002;571-586.
31. Timms P.M., Simmonds H.A., Bold A.M. Marked hypouricemia in purine nucleoside phosphorylase deficiency-serendipitous finding on screen. Clin. Chem. 42:1966;985.
32. Mably E.R., Fung E., Snyder F.F. Genetic deficiency of purine nucleoside phosphorylase in the mouse. Characterization of partially and severely enzyme deficient mutants. Genome. 32:1989;1026-1032.
33. Dju M.Y., Yu T.-F. Uric acid metabolism in homozygous and heterozygous muscular dystrophic mice. Am. J. Physiol. 234:1978;E421-E425.